Hans-Peter Kiem (Fred Hutch)
February 11, 2021 07:31 AM ESTUpdated February 12, 10:37 AM
Financing

Sana gets a com­peti­tor as Take­da, 5AM pour $170M in­to a Fred Hutch pi­o­neer's quest to un­seat CAR-T, ex vi­vo gene ther­a­py

Jason Mast

Editor

Over the last decade, Hans-Pe­ter Kiem, the Fred Hutch stem cell bi­ol­o­gist, and 5AM Ven­tures chief Kush Par­mar found­ed a slate of promi­nent biotechs, in­clud­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times